Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a $10 billion deal, adding a newly commercial endocrinology asset and additional late-stage pipeline programs. The purchase price is $10 billion, or about $85 per share, with Vertex to pick up Crinetics’ launched drug Palsonify for acromegaly and a therapy in late-stage development for congenital adrenal hyperplasia, according to company announcements. Crinetics boards approved the transaction and the deal is expected to close in the third quarter of 2026, signaling continued consolidation in commercial-stage specialty biotech. The acquisition follows a rapid run of oncology and targeted therapy moves at large pharma, with Vertex leaning into endocrinology commercialization as a complement to its core therapeutic areas.